Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BARRY J KUTTNER

Allopathic & Osteopathic Physicians Dermatology

NPI
1487614293
CMS profile
111852
Location
DELRAY BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$165.30

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $165.30 8

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $44.61 2
Novartis Pharmaceuticals Corporation $44.54 2
Amgen Inc. $35.92 2
Biofrontera Inc. $21.33 1
Regeneron Healthcare Solutions, Inc. $18.90 1

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BARRY J KUTTNER

NPI 1487614293 · CMS profile ID 111852

Allopathic & Osteopathic Physicians / Dermatology

DELRAY BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487614293?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BARRY J KUTTNER, NPI 1487614293, CMS profile ID 111852. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487614293?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). BARRY J KUTTNER, NPI 1487614293, CMS profile ID 111852. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487614293?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
BARRY J KUTTNER, NPI 1487614293, CMS profile ID 111852, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1487614293?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $165.30 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $12.1110/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939881951 CMS
PFIZER INC. $25.9810/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949628395 CMS
Novartis Pharmaceuticals Corporation $20.8610/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893865697 CMS
Amgen Inc. $23.8109/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939881949 CMS
Biofrontera Inc. $21.3305/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928734271 CMS
Regeneron Healthcare Solutions, Inc. $18.9004/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927245949 CMS
PFIZER INC. $18.6303/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949620151 CMS
Novartis Pharmaceuticals Corporation $23.6801/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893865693 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $47.55 3
PY2020 $77.30 5
PY2021 $264.26 16
PY2022 $165.30 8
PY2023 $138.69 6
PY2024 $4.04 1
PY2025 $51.95 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $700.00 1
PY2023 Principal investigator $16,868.27 29
PY2022 Principal investigator $44,738.46 42
PY2021 Recipient $11,453.00 4
PY2021 Principal investigator $67,841.53 50
PY2020 Principal investigator $261,290.81 68
PY2019 Recipient $27,860.00 6
PY2019 Principal investigator $204,941.02 55

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

68 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AbbVie Inc. $160.00 12/30/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
M16-045 No dispute reported 06/30/2026 721202571
Principal investigator 1 AbbVie Inc. $2,502.50 12/30/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
M16-045 No dispute reported 06/30/2026 721202573
Principal investigator 1 PFIZER INC. $9,969.13 12/17/2020 Non-covered Recipient Entity
Integrated Clinical Research LLC
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742898111
Principal investigator 1 Bausch Health US, LLC $250.00 12/14/2020 Non-covered Recipient Individual A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737375509
Principal investigator 1 LEO Pharma AS $3,614.00 11/24/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
LONG-TERM EXTENSION TRIAL IN SUBJECTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS TRALOKINUMAB TRIALS - ECZTEND No dispute reported 06/30/2026 746673713
Principal investigator 1 Bausch Health US, LLC $250.00 11/13/2020 Non-covered Recipient Individual A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737375345
Principal investigator 1 Bausch Health US, LLC $5,670.00 11/13/2020 Non-covered Recipient Individual A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737375359
Principal investigator 1 PFIZER INC. $625.75 10/30/2020 Non-covered Recipient Entity
Integrated Clinical Research LLC
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742910949
Principal investigator 1 PFIZER INC. $1,134.00 10/17/2020 Non-covered Recipient Entity
Integrated Clinical Research LLC
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742907969
Principal investigator 1 Janssen Research & Development, LLC $3,392.25 10/09/2020 Non-covered Recipient Entity
Integrated Clincal Rsrch Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719503143
Principal investigator 1 Bausch Health US, LLC $250.00 10/05/2020 Non-covered Recipient Individual A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737375229
Principal investigator 1 Bausch Health US, LLC $4,477.50 10/05/2020 Non-covered Recipient Individual A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737375247
Principal investigator 1 AbbVie Inc. $3,846.25 09/30/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
M16-045 No dispute reported 06/30/2026 721187997
Principal investigator 1 AbbVie Inc. $640.00 09/23/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
M16-766 No dispute reported 06/30/2026 721186445
Principal investigator 1 Bausch Health US, LLC $250.00 09/14/2020 Non-covered Recipient Individual A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737375157
Principal investigator 1 Bausch Health US, LLC $14,364.00 09/08/2020 Non-covered Recipient Individual A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737375151
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 08/24/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 724473929
Principal investigator 1 Janssen Research & Development, LLC $13,190.50 08/21/2020 Non-covered Recipient Entity
Integrated Clincal Rsrch Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719503139
Principal investigator 1 AbbVie Inc. $2,601.25 07/30/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
M16-045 No dispute reported 06/30/2026 721177535
Principal investigator 1 Bausch Health US, LLC $765.00 07/24/2020 Non-covered Recipient Individual A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737374859
Principal investigator 1 Janssen Research & Development, LLC $33.10 07/17/2020 Non-covered Recipient Entity
Integrated Clincal Rsrch Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719503127
Principal investigator 1 Janssen Research & Development, LLC $75.00 07/17/2020 Non-covered Recipient Entity
Integrated Clincal Rsrch Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719503131
Principal investigator 1 Janssen Research & Development, LLC $9,646.75 07/17/2020 Non-covered Recipient Entity
Integrated Clincal Rsrch Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719503135
Principal investigator 1 PFIZER INC. $6,500.00 07/17/2020 Non-covered Recipient Entity
Integrated Clinical Research LLC
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742906927
Principal investigator 1 AbbVie Inc. $297.50 07/16/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
M16-045 No dispute reported 06/30/2026 721176047
Principal investigator 1 Bausch Health US, LLC $250.00 07/13/2020 Non-covered Recipient Individual A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737374803
Principal investigator 1 AbbVie Inc. $293.75 07/06/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
M16-045 No dispute reported 06/30/2026 721174747
Principal investigator 1 Bausch Health US, LLC $2,947.50 07/03/2020 Non-covered Recipient Individual A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737374767
Principal investigator 1 Bausch Health US, LLC $700.00 07/03/2020 Non-covered Recipient Individual A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737374775
Principal investigator 1 Janssen Research & Development, LLC $575.00 06/19/2020 Non-covered Recipient Entity
Integrated Clincal Rsrch Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719503111
Principal investigator 1 Janssen Research & Development, LLC $250.00 06/19/2020 Non-covered Recipient Entity
Integrated Clincal Rsrch Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719503115
Principal investigator 1 Janssen Research & Development, LLC $12,715.00 06/19/2020 Non-covered Recipient Entity
Integrated Clincal Rsrch Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719503119
Principal investigator 1 Janssen Research & Development, LLC $9,329.50 06/19/2020 Non-covered Recipient Entity
Integrated Clincal Rsrch Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719503123
Principal investigator 1 Janssen Research & Development, LLC $10,105.75 06/06/2020 Non-covered Recipient Entity
Integrated Clincal Rsrch Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719503097
Principal investigator 1 Janssen Research & Development, LLC $75.00 06/06/2020 Non-covered Recipient Entity
Integrated Clincal Rsrch Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719503101
Principal investigator 1 Janssen Research & Development, LLC $18.88 06/06/2020 Non-covered Recipient Entity
Integrated Clincal Rsrch Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719503105
Principal investigator 1 AbbVie Inc. $6,139.75 06/01/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
M16-045 No dispute reported 06/30/2026 721169237
Principal investigator 1 AbbVie Inc. $120.00 05/26/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
M16-045 No dispute reported 06/30/2026 721166965
Principal investigator 1 AbbVie Inc. $3,500.00 05/19/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
M16-046 No dispute reported 06/30/2026 721166253
Principal investigator 1 VYNE Pharmaceuticals Inc. $900.00 05/19/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
MTI-117 No dispute reported 06/30/2026 753087489
Principal investigator 1 Janssen Research & Development, LLC $14.86 05/06/2020 Non-covered Recipient Entity
Integrated Clincal Rsrch Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719503081
Principal investigator 1 Janssen Research & Development, LLC $67,458.25 05/06/2020 Non-covered Recipient Entity
Integrated Clincal Rsrch Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719503089
Principal investigator 1 Janssen Research & Development, LLC $16.01 05/06/2020 Non-covered Recipient Entity
Integrated Clincal Rsrch Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719503093
Principal investigator 1 AbbVie Inc. $500.00 05/05/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
M16-045 No dispute reported 06/30/2026 721165075
Principal investigator 1 AbbVie Inc. $2,026.25 04/30/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
M16-045 No dispute reported 06/30/2026 721163171
Principal investigator 1 Bausch Health US, LLC $5,450.00 04/30/2020 Non-covered Recipient Individual A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737374053
Principal investigator 1 Bausch Health US, LLC $5,450.00 04/27/2020 Non-covered Recipient Individual A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737373985
Principal investigator 1 PFIZER INC. $6,500.00 04/21/2020 Non-covered Recipient Entity
Integrated Clinical Research LLC
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742909683
Principal investigator 1 Janssen Research & Development, LLC $75.00 04/17/2020 Non-covered Recipient Entity
Integrated Clincal Rsrch Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719503085
Principal investigator 1 AbbVie Inc. $3,503.75 04/16/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
M16-045 No dispute reported 06/30/2026 721160841
Principal investigator 1 Bausch Health US, LLC $5,450.00 04/06/2020 Non-covered Recipient Individual A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 737373909
Principal investigator 1 AbbVie Inc. $1,073.75 04/01/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
M16-045 No dispute reported 06/30/2026 721159511
Principal investigator 1 AbbVie Inc. $1,201.25 03/30/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
M16-045 No dispute reported 06/30/2026 721157797
Principal investigator 1 AbbVie Inc. $1,753.75 03/24/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
M16-766 No dispute reported 06/30/2026 721156625
Principal investigator 1 VYNE Pharmaceuticals Inc. $6,050.00 03/20/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
MTI-117 No dispute reported 06/30/2026 753087493
Principal investigator 1 AbbVie Inc. $112.50 03/19/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
M16-766 No dispute reported 06/30/2026 721156085
Principal investigator 1 LEO Pharma AS $325.00 03/18/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
LONG-TERM EXTENSION TRIAL IN SUBJECTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS TRALOKINUMAB TRIALS - ECZTEND No dispute reported 06/30/2026 746667985
Principal investigator 1 Janssen Research & Development, LLC $7,550.00 03/05/2020 Non-covered Recipient Entity
Integrated Clincal Rsrch Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719503065
Principal investigator 1 Janssen Research & Development, LLC $3,597.30 03/05/2020 Non-covered Recipient Entity
Integrated Clincal Rsrch Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719503069
Principal investigator 1 Janssen Research & Development, LLC $177.00 03/05/2020 Non-covered Recipient Entity
Integrated Clincal Rsrch Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719503073
Principal investigator 1 Janssen Research & Development, LLC $17.53 03/05/2020 Non-covered Recipient Entity
Integrated Clincal Rsrch Llc
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 719503077
Principal investigator 1 LEO Pharma AS $2,405.00 03/03/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
LONG-TERM EXTENSION TRIAL IN SUBJECTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS TRALOKINUMAB TRIALS - ECZTEND No dispute reported 06/30/2026 746667359
Principal investigator 1 AbbVie Inc. $1,398.75 02/28/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
M16-045 No dispute reported 06/30/2026 721152817
Principal investigator 1 AbbVie Inc. $500.00 02/26/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
M16-045 No dispute reported 06/30/2026 721152163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 02/24/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 724455867
Principal investigator 1 LEO Pharma AS $1,264.00 01/28/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
LONG-TERM EXTENSION TRIAL IN SUBJECTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS TRALOKINUMAB TRIALS - ECZTEND No dispute reported 06/30/2026 746666411
Principal investigator 1 AbbVie Inc. $3,603.75 01/13/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
M16-045 No dispute reported 06/30/2026 721145091
Principal investigator 1 AbbVie Inc. $792.50 01/03/2020 Non-covered Recipient Entity
INTEGRATED CLINICAL RESEARCH LLC
M16-766 No dispute reported 06/30/2026 721144225